Table 1.
Patient demographics and disease characteristics.
| Patient demographics and disease characteristics | Number of patients |
|---|---|
| Age (median, range) | 60 (range. 24–87 years) |
| Gender, M: F | 63: 40 |
| Synchronous liver disease | 81: 22 |
| Pathologic evidence of vascular invasion from primary tumor (yes/no/unknown) | 44: 33: 26 |
| KRAS mutation (yes/no/unknown) | 29: 33: 16 |
| PIK3CA mutation (yes/no/unknown) | 10: 41: 52 |
| Surgical resection of primary disease (yes/no/unknown) | 82: 20: 1 |
| CEA level before RAE (median, range ng/ml) | 55.3 (1.1–23937.6) |
| Time from diagnosis of CRC to diagnosis of CLM (mean, median, range, in months) | 6.3; 0 (range 0–64.2) |
| Time from diagnosis of CLM to RAE (median, range) | 30.9 (range. 3.4–161.7) |
| Type of microspheres (resin/glass/both) | 81: 21: 1 |
| Prior liver surgery (yes/no) | 49: 54 |
| Prior HAIP chemotherapy (yes/no) | 53: 50 |
| Prior systematic chemotherapy (≥3 lines vs. <3 lines) | 30: 73 |
| Prior bevacizumab (yes/no) | 63: 40 |
| Extent of hepatic replacement by tumor at time of RAE (<25%; ≥25%) | 89: 14 |
| Presence of extrahepatic disease at time of RAE (yes/no) | 74: 29 |
| Number of confirmed metastatic extrahepatic organ systems at time of RAE (0: 1: 2: 3: 4) | 29: 38: 24: 9: 3 |
| ECOG status at time of RE (Grade 0/1/2/unknown) | 33: 26: 2: 42 |
| Distribution of hepatic disease at time of RAE (unilobar/unilobar with one hepatic lobe center/bilobar) | 17: 11: 75 |
| Incidence of stasis in resin microspheres infusions | 39/146 (27%) |
| % of prescribed radiation dose delivered to tumor per procedure | 96% (range. 19–106%) |
| Number of RAE sessions per patients (one/two) | 73: 30 |
| Post-RAE HAIP* therapy (yes/no) | 18: 85 |
| Number of post-RAE systemic chemotherapy lines (0: 1: 2: 3: 4: unknown) | 25: 39: 22: 15: 1 |
| Post-RAE ablation (yes/no) | 5: 98 |
*
HAIP-hepatic arterial infusion pump therapy; CEA-carcinoembryonic antigen level; CRC-colorectal cancer; CLM-colorectal liver metastases; RAE-radioembolization.